Dare Bioscience Secures $215K in Equity Offering, Issuing Preferred Stock and Warrants
DARE is trading near its 52-week low of $1.42 (2.1% above the low) on light trading volume (0.4× avg).
Summary
Dare Bioscience completed a $215,250 equity unit offering, issuing preferred stock and warrants, providing additional capital for the company.
Key Events · Financing and Capital Events · DARE
-
Equity Offering Closing
Dare Bioscience completed a closing of its Regulation A offering on March 16, 2026, issuing 43,050 Investor Units.
-
Capital Raised
The company raised an aggregate of $215,250 from the sale of these units, with each Investor Unit offered at a price of $5.00.
-
Securities Issued
Each Investor Unit consisted of one share of Series A Convertible Preferred Stock and two warrants to purchase common stock, totaling 43,050 preferred shares and 86,100 warrants.
Analysis · DARE · Life Sciences
Dare Bioscience, a life sciences company, announced the closing of a tranche of its previously announced Regulation A offering, raising $215,250 through the sale of units comprising convertible preferred stock and warrants. This capital raise, while inherently dilutive, provides additional funding for the company, which is currently trading near its 52-week low. The successful completion of this offering helps extend the company's financial runway, following closely on the heels of a $2.0 million NIH grant announced yesterday, indicating ongoing efforts to secure necessary capital.
At the time of this filing, DARE was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.7M. The 52-week trading range was $1.42 to $9.19. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.